Updates are available Correction dated 2019-10-03
Click to view Correction: https://doi.org/10.1038/s41590-019-0528-5
-
Authors
Miller, Brian C. https://orcid.org/0000-0001-5931-4184
Sen, Debattama R. https://orcid.org/0000-0002-0947-8284
Al Abosy, Rose https://orcid.org/0000-0001-5400-1306
Bi, Kevin
Virkud, Yamini V.
LaFleur, Martin W. https://orcid.org/0000-0002-5017-774X
Yates, Kathleen B.
Lako, Ana
Felt, Kristen
Naik, Girish S.
Manos, Michael
Gjini, Evisa
Kuchroo, Juhi R.
Ishizuka, Jeffrey J.
Collier, Jenna L. https://orcid.org/0000-0002-4071-4986
Griffin, Gabriel K.
Maleri, Seth
Comstock, Dawn E.
Weiss, Sarah A.
Brown, Flavian D.
Panda, Arpit
Zimmer, Margaret D.
Manguso, Robert T.
Hodi, F. Stephen
Rodig, Scott J.
Sharpe, Arlene H.
Haining, W. Nicholas https://orcid.org/0000-0001-7871-3762
- License Information
-
More Information
Article History
Received: 12 June 2018
Accepted: 3 January 2019
First Online: 18 February 2019
Change Date: 3 October 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: W.N.H. receives funding from Roche and Novartis. A.H.S. has patents on the PD-1 pathway licensed by Roche/Genentech and Novartis and consults for Novartis. S.J.R. receives research support from Bristol-Myers Squibb, Merck, Affimed, and KITE pharmaceuticals. G.S.N. is a current employee of Leap Therapeutics. F.S.H. receives research support from Bristol-Myers Squibb, personal fees from Bristol-Myers Squibb, Merck, EMD Serono, Novartis, Celldex, Amgen, Genentech/Roche, Incyte, Apricity, Bayer, Aduro, Partners Therapeutics, Sanofi, Pfizer, Pionyr, Verastem, Compass Therapeutics, and Takeda. F.S.H. is an advisor for 7 Hills Pharma and Torque. F.S.H. has the following patents: Methods for Treating MICA-Related Disorders (no. 20100111973) with royalties paid, Tumor antigens and uses thereof (no. 7250291) issued, Angiopoiten-2 Biomarkers Predictive of Anti-immune checkpoint response (no. 20170248603) pending, Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms (no. 20160340407) pending, Therapeutic peptides (no. 20160046716) pending, Therapeutic Peptides (no. 20140004112) pending, Therapeutic Peptides (no. 20170022275) pending, Therapeutic Peptides (no. 20170008962) pending, Therapeutic Peptides (no. 9402905) issued and Methods of Using Pembrolizumab and Trebananib pending.
